New oxygen drug NanO2 tested in patients at risk of ventilator
NCT ID NCT06658535
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a drug called NanO2, which is designed to carry oxygen in the blood. It is being given to 18 hospitalized patients with mild respiratory distress who need extra oxygen but are not yet on a breathing machine. The main goal is to find the safest dose and check for side effects, with a future study planned if this goes well.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NanO2 (dodecafluoropentane)
What this could lead to
If successful, this could lead to a new way to deliver oxygen to patients with mild breathing problems, potentially reducing the need for mechanical ventilation.
What could go wrong
This is a very early Phase 1 trial with only 18 participants, focused on safety and dosing. It is too small to prove effectiveness, and the treatment may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD RESPIRATORY DISTRESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Grey Nun Community Hospital
RECRUITINGEdmonton, Alberta, T6L 5X8, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Maisonneuve Rosemont
RECRUITINGMontreal, Quebec, H1T 2M4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact